INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION
ULTIMAG TABLETS

SCHEDULING STATUS:
Not scheduled

PROPRIETARY NAME
(and dosage form):

ULTIMAG TABLETS

COMPOSITION:
Filmcoated tablets containing:

	Magnesium chloride B.P.	660 mg
	Zinc oxide	6 mg

PHARMACOLOGICAL CLASSIFICATION:
A.24. Mineral substitutes and electrolytes.

INDICATIONS:
For the supplementation of magnesium and zinc in cases of insufficient intake.

CONTRA-INDICATIONS:
Renal impairment, dehydration and gastric lesions and disorders.

DOSAGE AND DIRECTIONS FOR USE:
Take 2 to 4 tablets daily. It is recommended to take the major dose at night.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Diarrhoea, nausea and bowel discomfort may occur. Magnesium chloride should be given with caution to patients receiving digitalis glycosides. Concurrent administration with zinc salt might diminish the effect of penicillamine. Tetracyclines may form a chelate with zinc.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
Symptoms of hypermagnesemia may include flushing of the skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, loss of tendon reflexes due to neuromuscular blockade, muscle weakness, respiratory depression, cardiac arrhythmias, coma, and cardiac arrest.
Treatment is symptomatic and supportive.

IDENTIFICATION:
White, capsule-form tablets.

PRESENTATION:
ULTIMAG is supplied in amber glass bottles containing 30, 60 or 100 tablets.

STORAGE INSTRUCTIONS:
Store under 25°C in a cool dry place.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:
X/24/79

NAME AND BUSINESS ADDRESS OF THE APPLICANT:
MIRREN (PTY) LTD
18 Golden Drive, Morehill, Benoni.

DATE OF PUBLICATION:
9 November 1989
                Unified

Updated on this site: February 2001
SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2000